Preparation of artificial antigen and egg yolk-derived immunoglobulin (IgY) of florfenicol amine for ELISA assay.

To investigate the feasibility of IgY technology for the immune detection of haptens, a specific egg yolk antibody (IgY) has been developed in order to detect the florfenicol amine (FFA) residues. FFA was conjugated to bovine serum albumin (BSA) by glutaraldehyde (GA) and the conjugate was used to immunize laying chickens. Anti-FFA IgY antibody was purified by PEG-6000 precipitation and identified by SDS-PAGE. The titer of anti-FFA IgY antibody reached a peak of 1:128,000 after three booster injections. Checkerboard titration showed that a 1:800 dilution of anti-FFA IgY could give an optical density (OD) at around 1.0 at 10 µg/mL FFA-OVA coating concentration. An indirect competitive enzyme-linked immunosorbent assay (icELISA) using specific anti-FFA IgY showed that the IC50 value of anti-FFA IgY was 12.30 ng/mL and the regression curve equation was y = -13.71x + 64.95 (R (2) = 0.945). The strategy of developing anti-hapten IgY antibody is that it may be further used as a new reagent for an immunoassay of hapten residues.

[Study of effectiveness of craving control with topiramate in patients with substance dependence disorders]. / Estudio de la efectividad del control del craving con topiramato en pacientes con trastornos por dependencia de sustancias.

INTRODUCTION: Effectiveness and tolerability of topiramate at 3 and 6 months was assessed in patients requesting dehabituation programs. METHODS: Observational, prospective, national and multicenter study of 6 months, in patients on treatment with topiramate, who fulfilled criteria for dependence of opiates according to ICD-10 participating in therapeutic programs of dehabituation, without concomitant psychiatric illnesses and any responsible relative. Main measures of effectiveness were retention rates, alcohol consumption and other illicit drugs by urine tests (opiates, cannabis, cocaine) and treatment needs by EuropASI scale. Other parameters were HAM-D, DAS-SV and SF-36. RESULTS: Patients with consumption by urine tests decreased from 94.1 % (n = 64) at baseline to 39.6 % (n = 19) after 6 months of treatment, as was seen by means of the mean score in EuropASI scale, for all substances except methadone. No consumption was accompanied by a low rate of relapse of 33.3 % at 6 months. Twenty one patients had adverse reactions (28 %). The most frequent adverse reactions were somnolence (n = 9; 12 %), paraesthesia (n = 5; 6.7 %) and depression (n = 4; 5.3 %). CONCLUSIONS: In real clinical practice, topiramate showed a good response with a relevant decrease of percent of patients with abuse or consumption, and a satisfactory tolerability profile for the treatment of patients with dependence on heroine, cocaine, and other opiates, showing better outcomes than those obtained in previous trials.

Estudio de la efectividad del control del craving con topiramato en pacientes con trastornos por dependencia de sustancias / Study of effectiveness of craving control with topiramate in patients with substance dependence disorders

Introducción. En la práctica clínica habitual se ha evaluado de eficacia y tolerabilidad d etopiramato a los 3 y 6 meses en pacientes que solicitaron programas de deshabituación. Métodos. Estudio observacional prospectivo, multicéntrico, topiramato, en pacientes con criterios de dependencia de opiáceos según la CIE-10 en programas terapéuticos de deshabituación, si otra patología psiquiátrica concomitante y con algún familiar responsable. Medidas principales de eficacia han sido: tasas de retención, consumo de alcohol y otras drogas de abuso en orina y necesidad de tratamiento del cuestionario EuropASI. Otros parámetros han sido las escalas HAM-D, DAS-SV y SF-36. Resultados. El número de pacientes consumidores según controles de orina descendió del 84,1% (n=64) basal al 39,6% (n=19) a los 6 meses de seguimiento, descenso que se reflejó también a partir de la puntuación media en el cuestionario EuropASI para todas las sustancias excepto la metadona. Esta alta tasa de no consumo se acompañó de una baja tasa de recaídas, del 33,3• a los 6 meses. Se registraron 21 pacientes con reacciones adversas (28%), siendo las reacciones adversas más frecuentes la somnolencia (n=9; 12%), las parestesias (n=5; 6,7%) y la depresión (n=4; 5,3%). Conclusiones. El topiramato mostró en condiciones asistenciales reales una buena respuesta, con una importante disminución del porcentaje de pacientes consumidores y un satisfactorio perfil de tolerabilidad en el tratamiento de pacientes con dependencia de heroína, cocaína y/u otros derivados opiáceos, mejorando los resultados obtenidos en ensayos clínicos previos (AU)

Introduction. Effectiveness and tolerability to topiramate at 3 and 6 months was assessed in patients requesting dehabituation programs. Methods. Observational, prospective, national and multicenter study of 6 months, in patients on treatment with topiramate, who fulfilled criteria for dependence of opiates according to ICD-10 participating in therapeutic programs of dehabituation, without concomitant psychiatric illnesses and any responsible relative. Main measures of dehabituation, without concomitant psychiatric illnesses and any responsible relative. Main measures of effectiveness were retention rates, alcohol consumption and other illicit drugs by urine test (opiates, cannabis, cocaine) and treatment needs by EuropASI scale, Other parameters were HAM-D, DAS-SV and SF-36. Results. Patients with consumptions by urine test decreased from 94.1% (n=64) at baseline to 39,6% (n=19) after 6 months of treatment, as was seen by means of the mean score in EuropASI scale, for all substances except methadone. No consumption was accompanied by a low rate of relapse of 33.3% at 6 months. Twenty one patients had adverse reactins (28%). The most frequent adverse reactions were somnolence (n=9, 13%), paraesthesia (n=5 6.7%) and depression (n=4; 5.3%). Conclusions. In real clinical practice, topiramate showed a good response with a relevant decrease of percent of patients with abuse or consumption, and a satisfactory tolerability profile for the treatment of patients with dependence on heroine, cocaine and other opiates, showing better outcome than those obtained in previous trials (AU)

Relationship between masculinity and feminity in drinking in alcohol-related behavior in a general population sample.

The relationship between gender-related personality traits, on one hand and drinking, permissiveness towards drinking, and social as well as personal problems associated to drinking on the other, was studied in a general population sample from the City of Morelia, Mexico. Four gender-related traits scales were used for measuring assertive and aggressive masculinity and affective and submissive feminity, in addition to a standardized questionnaire for assessing drinking and other associated behavior. Some of the main results showed that people with high scores in affective feminity were less willing to allow drinking. Men who adopted a submissive feminine role and women with high masculine aggressive scores were more permissive as regards drinking. Among men, assertive masculine and affective feminine traits were more characteristic among those who drank than among abtainers. Drinking among women was related to liberal attitudes towards drinking and to aggressive masculinity. As regards the number of drinks consumed per month, assertive masculinity and liberal attitudes among men and affective feminity and liberal attitudes among women predicted the number of drinks. Affective feminity was negatively related to drinking. Regarding drinking-associated problems, frequency of drunkenness and submissive feminity among males predicted greater personal and social problems. Among women, drunkenness frequency and number of drinks were the most significant predictors. Contrary to what has been found in other countries, gender was a better drinking predictor than gender-related personality traits.

Aplicación de un cuestionario de detección de casos psiquiátricos en dos poblaciones de la práctica médica general / Application a questionnaire for psychiatric case detection in 2 po of general practice

El Cuestionario General de Salud de Goldberg, es un instrumento de detección de casos, y fue aplicado en dos poblaciones de la práctica médica general. Con el propósito de determinar las dimensiones que mide el instrumento, se realizó un análisis factorial con los datos de cada población por separado, y se comparó la versión de 5 factores derivada de cada una. En los resultados se comparan los reactivos que tuvieron mayor peso en cada una de las poblaciones, así como la forma en que se agruparon. En términos generales, las mayores diferencias se observaron en la agrupación de los reactivos de ansiedad y depresión; sin embargo las diferencias de agrupación no impiden la posibilidad de derivar una sola versión breve y escalada del instrumento que sea aplicable a poblaciones con diferentes características sociodemográficas